[Ip-health] Top 7/10 selling drugs are biologics

Outterson, Kevin mko at bu.edu
Fri Nov 28 09:54:00 PST 2014

>From Fierce Pharma:

"... all [of the top 10 selling drugs] but Abilify, Advair and Crestor are biologics, so they're expected to avoid the huge patent cliff crashes that small-molecule drugs have to suffer. And Advair, which is already off patent, has held its own because of the difficulty of copying GSK's Diskus inhaler."

Kevin Outterson
Professor of Law & N. Neal Pike Scholar in Health and Disability Law - Boston University
Associate Fellow, Chatham House<http://www.chathamhouse.org/about-us/directory/199052>
Editor in Chief, Journal of Law, Medicine & Ethics<http://www.aslme.org/>
Blogging health law at The Incidental Economist<http://www.theincidentaleconomist.com/>
Research papers at SSRN<http://ssrn.com/author=340746> & Google Scholar<http://scholar.google.com/citations?user=m4to2LMAAAAJ&hl=en>
@koutterson  |  617 935 6517

More information about the Ip-health mailing list